FDA re­leas­es sec­ond Pfiz­er gene ther­a­py from clin­i­cal hold, as he­mo­phil­ia pro­gram gets OK to restart

The FDA has re­leased a clin­i­cal hold on Pfiz­er and Sang­amo’s he­mo­phil­ia A gene ther­a­py af­ter or­der­ing the com­pa­nies to stop the tri­al last year due to con­cerns about blood clots.

Just a week af­ter Pfiz­er an­nounced the FDA had un­leashed its gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy from a clin­i­cal hold — which was paused as one pa­tient died and oth­ers ex­pe­ri­enced se­vere side ef­fects  — an­oth­er one of its gene ther­a­py pro­grams has been giv­en the green light to re­sume, Pfiz­er an­nounced dur­ing its Q1 earn­ings call yes­ter­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER